Kornitzer Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Kornitzer Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-192,695	Closed	-$5.41M	–	506
2021 Q4	$5.41M	Hold	192,695	–	–	0.08%	267
2021 Q3	$6.55M	Sell	192,695 -436,405	-69%	-$15.8M	0.1%	263
2021 Q2	$25.7M	Hold	629,100	–	–	0.39%	78
2021 Q1	$25.3M	Buy	629,100 +60,000	+11%	+$3.25M	0.41%	73
2020 Q4	$33.7M	Sell	569,100 -2,890	-0.5%	-$149K	0.57%	42
2020 Q3	$27.8M	Buy	571,990 +375,490	+191%	+$15.8M	0.54%	46
2020 Q2	$9.51M	Sell	196,500 -1,620	-0.8%	-$59.1K	0.19%	175
2020 Q1	$5.5M	Buy	198,120 +96,170	+94%	+$2.68M	0.13%	211
2019 Q4	$3.05M	Buy	101,950 +44,320	+77%	+$1.27M	0.05%	291
2019 Q3	$1.78M	Buy	57,630 +22,630	+65%	+$924K	0.03%	344
2019 Q2	$1.69M	Buy	+35,000	New	+$1.55M	0.03%	358

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Kornitzer Capital Management's ADPT Position: Q1 2022 in Review

Kornitzer Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q1 2022, closing a stake of 192,695 shares — an estimated $5.41M sold.

Kornitzer Capital Management first reported a position in ADPT in Q2 2019 and held it in 11 quarters. The position peaked at $33.7M in Q4 2020. 221 funds tracked by Wall St. Rank hold ADPT as of Q1 2022.

Kornitzer Capital Management reported no remaining Adaptive Biotechnologies position as of Q1 2022 after selling out during the quarter.
Kornitzer Capital Management sold 192,695 Adaptive Biotechnologies shares in Q1 2022, an estimated $5.41M.
Kornitzer Capital Management first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 11 quarters.
Kornitzer Capital Management's Adaptive Biotechnologies position peaked at $33.7M in Q4 2020.
221 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2022.

Based on Kornitzer Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.